How ValiRx uses InvestorHub to communicate to a complex pipeline to a specialist investor base 

Your pipeline involves quite technical science — VAL201, VAL301, Inaphaea BioLabs. How do you use the platform to make that accessible?

"The updates function has been really valuable for this. Alongside our formal announcements, we publish regular content updates that explain what's happening in the pipeline in plain terms. That might be a summary of what a trial phase means in practice, or context around a partnering agreement we've signed. It sits separately from the RNS but is linked to it, so investors get the technical disclosure and the explanation side by side.

We've also found that the Q&A functionality helps us understand where the gaps are in our communications. If we're getting the same question about a particular compound repeatedly, that tells us we need to do a better job explaining it."